Ascendis Pharma A/S Proceeds From Exercise Of Warrants
Ascendis Pharma A/S (ASND) reported Proceeds From Exercise Of Warrants of EUR 87.08 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Cash Flow › Financing Activities
ifrs-full:ProceedsFromExerciseOfWarrants · last filed 2026-02-11
- Ascendis Pharma A/S proceeds from exercise of warrants for the quarter ending 2025-12-31 was 15.35M EUR, a 405.97% increase year-over-year.
- Ascendis Pharma A/S proceeds from exercise of warrants for the quarter ending 2025-09-30 was 45.42M EUR, a 669.13% increase year-over-year.
- Ascendis Pharma A/S proceeds from exercise of warrants for the quarter ending 2025-06-30 was 12.47M EUR, a 3315.89% increase year-over-year.
- Ascendis Pharma A/S proceeds from exercise of warrants for the quarter ending 2025-03-31 was 13.83M EUR, a 34.77% decline year-over-year.
| Period end | Proceeds From Exercise Of Warrants 3 month | Proceeds From Exercise Of Warrants 6 month | Proceeds From Exercise Of Warrants 9 month | Proceeds From Exercise Of Warrants 12 month |
|---|---|---|---|---|
| 2025-12-31 | 15.35M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | 60.78M EUR derived: sum of 2 quarters · filed 2026-02-11 | 73.24M EUR derived: sum of 3 quarters · filed 2026-02-11 | 87.08M EUR 20-F · filed 2026-02-11 |
| 2025-09-30 | 45.42M EUR derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | 57.89M EUR derived: sum of 2 quarters · filed 2025-11-12 | 71.73M EUR 6-K · filed 2025-11-12 | 74.76M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-06-30 | 12.47M EUR derived: 6-K 6 month − 6-K 3 month · filed 2025-08-07 | 26.30M EUR 6-K · filed 2025-08-07 | 29.34M EUR derived: sum of 3 quarters · filed 2026-02-11 | 35.24M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-03-31 | 13.83M EUR 6-K · filed 2025-05-01 | 16.87M EUR derived: sum of 2 quarters · filed 2026-02-11 | 22.77M EUR derived: sum of 3 quarters · filed 2026-02-11 | 23.14M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | 3.03M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | 8.94M EUR derived: sum of 2 quarters · filed 2026-02-11 | 9.30M EUR derived: sum of 3 quarters · filed 2026-02-11 | 30.51M EUR 20-F · filed 2026-02-11 |
| 2024-09-30 | 5.91M EUR derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | 6.27M EUR derived: sum of 2 quarters · filed 2025-11-12 | 27.48M EUR 6-K · filed 2025-11-12 | 29.50M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | 365.00K EUR derived: 6-K 6 month − 6-K 3 month · filed 2025-08-07 | 21.57M EUR 6-K · filed 2025-08-07 | 23.59M EUR derived: sum of 3 quarters · filed 2026-02-11 | 29.79M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | 21.21M EUR 6-K · filed 2025-05-01 | 23.23M EUR derived: sum of 2 quarters · filed 2026-02-11 | 29.42M EUR derived: sum of 3 quarters · filed 2026-02-11 | 29.63M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | 2.02M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | 8.21M EUR derived: sum of 2 quarters · filed 2026-02-11 | 8.42M EUR derived: sum of 3 quarters · filed 2026-02-11 | 10.29M EUR 20-F · filed 2026-02-11 |
| 2023-09-30 | 6.19M EUR derived: 6-K 9 month − 6-K 6 month · filed 2024-11-14 | 6.40M EUR derived: sum of 2 quarters · filed 2024-11-14 | 8.27M EUR 6-K · filed 2024-11-14 | 11.40M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | 208.00K EUR derived: 6-K 6 month − 6-K 3 month · filed 2024-09-03 | 2.07M EUR 6-K · filed 2024-09-03 | 5.20M EUR derived: sum of 3 quarters · filed 2025-02-12 | 6.54M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | 1.87M EUR 6-K · filed 2024-05-02 | 5.00M EUR derived: sum of 2 quarters · filed 2025-02-12 | 6.33M EUR derived: sum of 3 quarters · filed 2025-02-12 | 6.63M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | 3.13M EUR derived: 20-F 12 month − 6-K 9 month · filed 2025-02-12 | 4.47M EUR derived: sum of 2 quarters · filed 2025-02-12 | 4.77M EUR derived: sum of 3 quarters · filed 2025-02-12 | 5.15M EUR 20-F · filed 2025-02-12 |
| 2022-09-30 | 1.34M EUR derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | 1.64M EUR derived: sum of 2 quarters · filed 2023-11-07 | 2.02M EUR 6-K · filed 2023-11-07 | 4.35M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-06-30 | 301.00K EUR derived: 6-K 6 month − 6-K 3 month · filed 2023-09-05 | 686.00K EUR 6-K · filed 2023-09-05 | 3.01M EUR derived: sum of 3 quarters · filed 2024-02-07 | 7.44M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-03-31 | 385.00K EUR 6-K · filed 2023-04-27 | 2.71M EUR derived: sum of 2 quarters · filed 2024-02-07 | 7.14M EUR derived: sum of 3 quarters · filed 2024-02-07 | 9.94M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2021-12-31 | 2.33M EUR derived: 20-F 12 month − 6-K 9 month · filed 2024-02-07 | 6.75M EUR derived: sum of 2 quarters · filed 2024-02-07 | 9.55M EUR derived: sum of 3 quarters · filed 2024-02-07 | 11.54M EUR 20-F · filed 2024-02-07 |
| 2021-09-30 | 4.43M EUR derived: 6-K 9 month − 6-K 6 month · filed 2022-11-02 | 7.23M EUR derived: sum of 2 quarters · filed 2022-11-02 | 9.21M EUR 6-K · filed 2022-11-02 | |
| 2021-06-30 | 2.80M EUR derived: 6-K 6 month − 6-K 3 month · filed 2022-08-10 | 4.78M EUR 6-K · filed 2022-08-10 | ||
| 2021-03-31 | 1.98M EUR 6-K · filed 2022-05-11 | |||
| 2020-12-31 | 26.88M EUR 20-F · filed 2023-02-16 | |||
| 2019-12-31 | 17.38M EUR 20-F · filed 2022-03-02 |